carbamates has been researched along with Dementia in 19 studies
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function." | 9.10 | Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003) |
| "65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks." | 9.10 | A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002) |
| "Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)." | 7.72 | Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003) |
| "The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition." | 5.31 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002) |
| " We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia." | 5.10 | Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. ( Fogelson, N; Giladi, N; Kogan, E; Korczyn, AD; Neufeld, MY; Shabtai, H, 2003) |
| "Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function." | 5.10 | Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003) |
| "65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks." | 5.10 | A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002) |
| " Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea." | 5.05 | New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020) |
| "Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)." | 3.72 | Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003) |
| "Cholinesterase inhibitors (ChEIs) are dosed in two phases for the treatment of dementia, an initial dose-escalation phase to achieve a therapeutic dose and a maintenance phase where the therapeutic dose is given for long-term therapy." | 2.41 | The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. ( Inglis, F, 2002) |
| " Rivastigmine shows a clear dose-response relationship, and physicians should aim to maintain patients on doses of 6 mg/day or higher, to a maximum of 12 mg/day." | 2.41 | The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. ( Bullock, R, 2002) |
| "The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition." | 1.31 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Earl, DC | 1 |
| Van Tyle, KM | 1 |
| Lin, JN | 1 |
| Lin, CL | 1 |
| Lin, MC | 1 |
| Lai, CH | 1 |
| Lin, HH | 1 |
| Yang, CH | 1 |
| Kao, CH | 1 |
| Rösler, M | 1 |
| Inglis, F | 1 |
| Bullock, R | 2 |
| Cameron, A | 1 |
| Hartmann, S | 1 |
| Möbius, HJ | 1 |
| Fogelson, N | 1 |
| Kogan, E | 1 |
| Korczyn, AD | 3 |
| Giladi, N | 2 |
| Shabtai, H | 2 |
| Neufeld, MY | 1 |
| Werber, EA | 1 |
| Gandelman-Marton, R | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| GIBBS, AE | 1 |
| WYKES, PR | 1 |
| D AMELIO, V | 1 |
| ANNOVI, G | 1 |
| Fuchsberger, T | 1 |
| Möller, HJ | 1 |
| Hampel, H | 1 |
| Gurevich, T | 1 |
| Benbunan, B | 1 |
| Anca, M | 1 |
| Schneider, LS | 1 |
| Smith, DJ | 1 |
| Yukhnevich, S | 1 |
| Weiser, M | 1 |
| Rotmensch, HH | 1 |
| Hartman, R | 1 |
| Cicin-Sain, A | 1 |
| Anand, R | 1 |
| Tewfik, GI | 1 |
| Jain, VK | 1 |
| Harcup, M | 1 |
| Magowan, S | 1 |
7 reviews available for carbamates and Dementia
| Article | Year |
|---|---|
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; | 2020 |
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Topics: Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans | 2002 |
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Topics: Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic A | 2002 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
Understanding changes in cholinergic function: implications for treating dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibi | 2002 |
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dementia; Hum | 2002 |
5 trials available for carbamates and Dementia
| Article | Year |
|---|---|
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Dementia; Elec | 2003 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De | 2003 |
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Male; Parkinson Disease; P | 2003 |
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Dementia; D | 2002 |
Effectiveness of various tranquilisers in the management of senile restlessness.
Topics: Aged; Carbamates; Chlorpromazine; Clinical Trials as Topic; Dementia; Female; Haloperidol; Humans; H | 1970 |
7 other studies available for carbamates and Dementia
| Article | Year |
|---|---|
Increased Risk of Dementia in Patients With Acute Organophosphate and Carbamate Poisoning: A Nationwide Population-Based Cohort Study.
Topics: Adult; Aged; Carbamates; Cohort Studies; Dementia; Female; Humans; Incidence; Insecticides; Insuranc | 2015 |
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Hallucinations; Humans; Male; Parkins | 2002 |
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Res | 2003 |
The use of methylpentynol carbamate in a geriatric unit.
Topics: Carbamates; Dementia; Geriatrics; Humans; Mental Disorders; Psychotic Disorders | 1960 |
Sedation in geriatrics using methylpentynol carbamate.
Topics: Aged; Carbamates; Dementia; Geriatrics; Humans; Hypnotics and Sedatives; Mental Disorders; Psychotic | 1960 |
[TREATMENT WITH MEBUTAMATE (AN ANTIHYPERTENSIVE WITH CENTRAL ACTION) OF MENTAL PATIENTS WITH HYPERTENSIVE MANIFESTATIONS].
Topics: Alcoholism; Antihypertensive Agents; Anxiety; Bipolar Disorder; Carbamates; Dementia; Epilepsy; Huma | 1963 |
Adverse reactions to rivastigmine in three cases of dementia.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Carbamates; Cholinesterase Inhi | 2001 |